Mustang Bio, Inc. (MBIO)
0.533
-0.01
(-1.52%)
USD |
NASDAQ |
Sep 09, 13:07
Mustang Bio Enterprise Value : -11.05M for Sept. 8, 2026
Enterprise Value Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Enterprise Value Data
| Date | Value |
|---|---|
| September 08, 2026 | -11.05M |
| September 04, 2026 | -11.04M |
| September 03, 2026 | -10.91M |
| September 02, 2026 | -11.04M |
| September 01, 2026 | -11.00M |
| August 31, 2026 | -11.08M |
| August 28, 2026 | -11.08M |
| August 27, 2026 | -10.98M |
| August 26, 2026 | -10.91M |
| August 25, 2026 | -10.97M |
| August 24, 2026 | -10.97M |
| August 21, 2026 | -10.76M |
| August 20, 2026 | -10.81M |
| August 19, 2026 | -10.80M |
| August 18, 2026 | -10.83M |
| August 17, 2026 | -10.65M |
| August 14, 2026 | -10.65M |
| August 13, 2026 | -10.65M |
| August 12, 2026 | -10.56M |
| August 11, 2026 | -10.54M |
| August 10, 2026 | -10.68M |
| August 07, 2026 | -10.60M |
| August 06, 2026 | -10.79M |
| August 05, 2026 | -10.63M |
| August 04, 2026 | -10.65M |
| Date | Value |
|---|---|
| August 03, 2026 | -10.78M |
| July 31, 2026 | -10.83M |
| July 30, 2026 | -10.65M |
| July 29, 2026 | -10.76M |
| July 28, 2026 | -10.37M |
| July 27, 2026 | -10.91M |
| July 24, 2026 | -10.89M |
| July 23, 2026 | -10.83M |
| July 22, 2026 | -10.67M |
| July 21, 2026 | -10.48M |
| July 20, 2026 | -10.21M |
| July 17, 2026 | -10.39M |
| July 16, 2026 | -10.27M |
| July 15, 2026 | -10.36M |
| July 14, 2026 | -10.13M |
| July 13, 2026 | -10.12M |
| July 10, 2026 | -9.818M |
| July 09, 2026 | -9.543M |
| July 08, 2026 | -9.999M |
| July 07, 2026 | -9.772M |
| July 06, 2026 | -9.772M |
| July 02, 2026 | -9.823M |
| July 01, 2026 | -9.836M |
| June 30, 2026 | -9.831M |
| June 29, 2026 | -10.96M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| ACADIA Pharmaceuticals, Inc. | 3.865B |
| Alnylam Pharmaceuticals, Inc. | 34.46B |
| Anika Therapeutics, Inc. | 268.42M |
| Savara, Inc. | 993.23M |
| Vericel Corp. | 1.932B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -1.072M |
| Total Expenses (Quarterly) | 1.072M |
| EPS Diluted (Quarterly) | -0.1592 |
| Earnings Yield | -84.39% |
| Normalized Earnings Yield | -84.39 |